Equity Components [Axis]
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Debt Instrument [Axis]
Short Term Notes Payable [Member]
Convertible Notes Payable [Member]
Other Commitments [Axis]
Consulting Agreements [Member]
Related Party [Axis]
January 2016 [Member]
Financial Instrument [Axis]
Option [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Employee Agreement with Eric Clemons [Member]
Award Date [Axis]
On September 29, 2016 [Member]
Employee Agreement with Wesley Tate [Member]
Dr. Saini [Member]
On March 1, 2015 [Member]
Individuals [Member]
Class of Warrant or Right [Axis]
Stock Purchase Agreement [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Short Term Notes Payable to Stockholders [Member]
Convertible Notes Payable (A) [Member]
Sale of Stock [Axis]
Private Placement Memorandum [Member]
Warrants [Member]
Plan Name [Axis]
October 2016 [Member]
Warrant [Member]
Legal [Member]
July 2016 [Member]
Title of Individual [Axis]
Miriam Weber Miller Two [Member]
Transaction Type [Axis]
Transaction One [Member]
Miriam Weber Miller One [Member]
Miriam Weber Miller [Member]
Commitments [Member]
September 2012 [Member]
December 2016 and Jun 2018 [Member]
Short-term Debt, Type [Axis]
Short term notes payable (A) [Member]
Short term notes payable (B) [Member]
Convertible Notes Payable (B) [Member]
Convertible Note Payable (C) [Member]
January 2017 Convertible Note [Member]
Short Term Notes Payable to Stockholders One [Member]
In 2017 [Member]
Non-cashless warrant [Member]
Option Indexed to Issuer's Equity, Type [Axis]
Options outstanding [Member]
Options exercisable [Member]
December 2013 and December 2017 [Member]
Omnibus Stock Grant and Option Plan [Member]
On October 1, 2014 [Member]
On February 1, 2018 [Member]
Non Affiliate Stockholder [Member]
Short Term Convertible Notes Payable [Member]
Short Term Convertible Notes Conversion [Member]
Short Term Convertible Warrants Conversion [Member]
Related Party Transaction [Axis]
Crown Bridge Partners [Member]
Auctus Fund [Member]
EMA Financial [Member]
Measurement Frequency [Axis]
Derivative Liabilities [Member]
Warrants [Member]
Convertible Promissory Notes [Member]
Measurement Basis [Axis]
Fresh-Start Adjustments [Axis]
Revaluation of Liabilities [Member]
EMA Financial, LLC [Member]
Securities Purchase Agreement [Member]
Convertible Promissory Note [Member]
Auctus Fund, LLC [Member]
Report Date [Axis]
Tranche 1 [Member]
October 2017 Convertible Note [Member]
December 2015 Convertible Note [Member]
Unsecured, Amended and Consolidated Convertible Notes Payable [Member]
December 2014 Convertible Note [Member]
Additional Paid In Capital
Short term notes payable (C) [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Convertible Promissory Note [Member]
October 2017 [Member]
Crown Bridge Partners, LLC [Member]
Conversion 1 [Member]
Conversion 2 [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Common Stock, Shares Outstanding
Entity Public Float
Document Fiscal Period Focus
Document Fiscal Year Focus
Consolidated Balance Sheets
ASSETS
Current assets:
Cash and cash equivalents
Prepaid expenses
Total current assets
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable
Related party payables
Accrued payroll
Payroll taxes payable
Convertible notes to stockholders, current portion
Short term notes payable to stockholders
Short term convertible notes payable, net of debt discount of approximately $177,094 and $0, respectively
Derivative liabilities
Warrant liabilities
Total current liabilities
Long term liabilities:
Convertible notes to stockholders, net of current portion and net of debt discount of approximately $5,381 and $12,053, respectively
Total long-term liabilities
Total liabilities
Commitments and contingencies (Note 4)
Stockholders' deficit
Preferred stock ($0.001 par value: 1,000,000 shares authorized;none issued and outstanding)
Common stock ($0.001 par value: 249,000,000 shares authorized;9,039,347 and 7,880,347 shares issued and outstanding atJune 30, 2018 and 2017, respectively)
Additional paid in capital
Accumulated deficit
Total stockholders' deficit
Total liabilities and stockholders' deficit
Consolidated Balance Sheets
Convertible notes payable, net of debt discount
Convertible notes payable net of debt discount Non current
Preferred stock, par value
Preferred stock, authorized shares
Preferred stock, issued shares
Preferred stock, outstanding shares
Common stock, par value
Common stock, Authorized shares
Common stock, Issued shares
Common stock, outstanding shares
Consolidated Statements Of Operations
Operating Expenses
Selling, general and administrative expenses
Research and development costs
Patent Royalty Expense
Marketing expenses
Total operating expenses
Other (income) expense
Accretion of debt discount
Loss from extinguishment of debt
Interest expense
Change in fair value of derivative liabilities
Change in fair value of warrant liabilities
Total other expense, net
Operating loss
Loss before income taxes
Income taxes
Net loss
Loss per share:
Basic and diluted loss per share
Basic and diluted weighted average shares outstanding
Statement [Table]
Statement [Line Items]
Beginning Balance, Shares
Beginning Balance, Amount
Proceeds from issuance of common stock, net of offering costs, Shares
Proceeds from issuance of common stock, net of offering costs, Amount
Proceeds from exercise of warrants, Shares
Proceeds from exercise of warrants, Amount
Shares issued for services, Shares
Shares issued for services, Amount
Shares issued with convertible note payable, Shares
Shares issued with convertible note payable, Amount
Stock based compensation
Warrants issued for services
Debt discount associated with convertible notes payable beneficial conversion feature
Debt discount associated with convertible notes payable - warrant feature
Loss from extinguishment associated with debt discounts and finance costs
Proceeds from issuance of common stock and warrants, Shares
Proceeds from issuance of common stock and warrants, Amount
Shares issued for financing, Shares
Shares issued for financing, Amount
Stock based compensation, Shares
Stock based compensation, Amount
Net loss for the year
Ending Balance, Shares
Ending Balance, Amount
Consolidated Statements Of Cash Flows
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Initial fair value of derivative liabilities included as interest expense
Change in derivative liabilities
Change in warrant liabilities
Amortization of stock based prepaid consulting compensation
Stock compensation for legal services
Changes in operating assets and liabilities:
Prepaid expenses
Accounts payable
Related party payables
Accrued payroll and taxes
Net cash used in operating activities
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants
Proceeds from exercise of warrants
Proceeds from short term notes to stockholders
Proceeds from convertible notes
Proceeds from short term convertible notes, net
Repayment of convertible notes
Net cash flows provided by financing activities:
Net change in cash and cash equivalents
Cash and cash equivalents- beginning of period
Cash and cash equivalents- end of period
Supplemental disclosure of non-cash activities:
Cash paid during the period for: Interest
Cash paid during the period for: Income tax
Supplemental disclosure on non-cash investing and financing activities:
Debt discount associated with convertible notes payable - beneficial conversion feature
Stock issued for prepaid services
Embedded derivative recorded as debt discount
Derivative warrant liability recorded as debt discount
Debt issuance cost recorded as debt discount
Warrants issued for prepaid services
Conversion of convertible notes payable and interest to stock
Debt discount associated with related party notes payable - stock issued
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES
NOTE 2 - BASIS OF PRESENTATION
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 4 - COMMITMENTS AND CONTINGENCIES
NOTE 5 - PATENT RIGHTS
NOTE 6 - NOTES PAYABLE
NOTE 7 - STOCK TRANSACTIONS
NOTE 8 - OPTIONS AND WARRANTS
NOTE 9 - RELATED PARTY TRANSACTIONS
NOTE 10 - EARNINGS PER SHARE
NOTE 11 - INCOME TAXES
NOTE 12 - SUBSEQUENT EVENTS
Summary Of Significant Accounting Policies
Use of Estimates
Principles of Consolidation
Advertising Costs
Research and Development
Debt
Debt with warrants
Convertible debt derivative treatment
Convertible debt beneficial conversion feature
Debt Modifications and Extinguishments
Fair Value of Financial Instruments
Fair Value Measurements
Concentrations, Risks, and Uncertainties
Basic and Diluted Earnings Per Share
Recent Accounting Pronouncements
Commitments And Contingencies
Schedule of Future Maturity of Prepaid Expense
Summary of note payable
Future maturities of convertible notes payable
Schedule of fair value of the embedded derivative liabilities
Schedule changes in the derivative and warrant liabilities
Options And Warrants
Options outstanding
Warrants outstanding
Earnings Per Share
Computation of basic and diluted net income per share
Income Taxes
Provision for income tax effective tax rate
Deferred income tax assets
Organization And Principal Activities
State of incorporation
Date of incorporation
Basis Of Presentation
Net cash used in operating activities
Summary Of Significant Accounting Policies
Advertising costs
Commitments And Contingencies
2019
Total
Award Type [Axis]
Restricted common stock shares issued
Exercise price
Fair market value option
Fair Value Volatility rate
Fair Value Risk-free interest rate
Fair Value Expected term
Fair Value Dividend yield
Selling, general and administrative expense
Unamortized prepaid expense
Company paid approximately amount
Incurred balance
Prepaid expense
Compensation issuance shares
Breach of contract damages
Breach of contract damages payable
Monthly payments
Payment of accounts payable
Legal fees
Patent royalty expense
Accrued payable
Patent license agreement fees
Stock issued
Market value on share issued
2014
2015
2016
Thereafter
Estimated useful life of patent
Royalty payment percentage
Equity participation percentage
Subtotal
Debt discount
Short term convertible notes payable, net of debt discount of approximately $261,250 and $0, respectively
Expected dividend yield
Expected stock-price volatility
Risk-free interest rate
Stock price
Conversion price
Derivative liabilities:
Derivative liabilities, Beginning balance
Increase (decrease) in fair value
Derivative liabilities, Outstanding balance
Warrant liabilities:
Warrant liabilities, Beginning balance
Increase in fair value
Warrant liabilities, Outstanding balance
Convertible Notes Payable
Debt discount
Convertible Notes to Stockholders
Notes Payable
2019
2020
Total outstanding notes
Debt Discount
Net Notes Payable
Credit facility maximum borrowing capacity
Original issue discount
Credit facility maximum borrowing capacity net of debt discount
Proceeds from related party debt including portion attributable to debt discount
Proceeds from related party debt
Interest rate
Maturity date description
Terms of conversion feature
Description for event of default
Description of prepayment of debt
Description of warrants issuable under agreement
Common stock shares issuable upon exercise of warrants or rights
Exercise price
Gain on embedded derivative liability re-valuation
Loss on re-valuation of warrant liability
Debt discount
Amortization of debt discount
Accretion of debt discount
Accretion of debt discount to be recognized in future
Related party notes payable maturity date
Accrued interest percentage
Notes payable additional amount
Related party short term notes payable
Common stock, issued shares
Unsecured promissory note
Converted amount
Repayment of debt
Balance amount
Maturity date
Common stock rate, per share
Note holder acquire percentage
Common stock granted in cashless option
Exercise price
Fully vested options expire period
Beneficial conversion amount
Accretion of debt discount expense in future
Common stock issued to Convertible notes
Debt default
Notes payable included in consolidation
Cash received from notes payable
Estimated relative fair value discount
Volatility rate
Expected term
Dividend yield
Loss from extinguishment of debt
Accounts payable related to accrued interest
Interest expense on notes payable
Debt discount cost
Common stock issued for purchase, shares
Common stock issued for purchase, amount
Exercise price
Warrants reserved for future issuance
Share price
Number of units authorized
Description of units authorized
Convertible debenture issuable for each unit
Non-cashless warrant issuable for each unit
Conversion price
Prepaid expense
Additional share of common stocks
Common stock shares issued
Common stock share exchange value
Options
Outstanding, beginning of year
Granted
Exercised
Expired/Forfeited
Outstanding, ending balance
Exercisable, ending balance
Expected to be vested
Compensation to be recognized
Forfeiture Rate
Options Average Exercise Price
Outstanding, beginning of year
Granted
Exercised
Expired/Forfeited
Outstanding, ending price
Exercisable, ending balance
Expected to be vested
Forfeiture Rate
Weighted Average Contractual Life
Outstanding, beginning of year
Granted
Outstanding, ending balance
Exercisable, ending balance
Expected to be vested
Aggregate Intrinsic Value
Outstanding, beginning of year
Outstanding, end of year
Warrants
Weighted Average Exercise Price
Number of securities to be issued upon exercise of outstanding options, warrants and rights
Weighted-average exercise price of options, warrants and rights
Weighted average contractual life
Number of securities remaining available for future issuance under equity compensation plan (excluding securities reflected in column (a))
Expense recognized
Compensation expected to be recognized
Annual salary
Common stock shares option
Stock options to purchase vested
Compensation expected to be recognized in future cost
Prepaid expense unamortized
Cash placement bonus
Aggregate purchase price
Terms of contract
Shares issued
Earnings Per Share
Net loss attributable to the common stockholders
Basic weighted average outstanding shares of common stock
Dilutive effect of options and warrants
Diluted weighted average common stock and common stock equivalents
Earnings (loss) per share:
Basic and diluted
Total dilutive warrants
Exercise price of convertible notes
Common stock shares issuable upon conversion of convertible notes
Income Taxes
Current tax provision:
Federal
Taxable income - federal
State
Taxable income - state
Total current tax provision
Deferred tax provision:
Federal and State
Total deferred tax provision
Income Taxes
Loss carryforwards
Less - valuation allowance
Total net deferred tax assets
Income Taxes
Effective tax rate for federal income taxes
Expiry year
Promissory note principal amount
Promissory note modified in exchange of a new promissory note
Accrued interest
Proceeds from issuance of promissory note
Interest rate
Debt conversion amount converted or elected to be converted
Debt conversion amount converted or elected to be converted, principal
Debt conversion amount converted or elected to be converted, fees
Common stock shares issued upon conversion of debt
Debt conversion amount converted or elected to be converted, accrued and unpaid interest
Contract Eight [Member]
Contract Eleven [Member]
Contract Fifteen [Member]
Contract Five [Member]
Contract Four [Member]
Contract Fourteen [Member]
Contract Nine [Member]
Contract One [Member]
Contract Seven [Member]
Contract Six [Member]
Contract Ten [Member]
Contract Thirteen [Member]
Contract Three [Member]
Contract Twelve [Member]
Contract Two [Member]
Market value on share issued.
Patent license agreement fees.
Schedule of Maturity of Prepaid Expense.
It represent yearly minimum royalty payments in 2015.
It represent yearly minimum royalty payments in 2016.
It represent yearly minimum royalty payments in 2014.
It represent yearly minimum royalty payments thereafter.
WarrantsMember
ConvertiblePromissoryNotePayableMember
Assets, Current
Assets
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses [Default Label]
Other Nonoperating Expense
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Due to Related Parties, Current
Repayments of Convertible Debt
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Time Deposit Maturities, Year Three
Debt Instrument, Unamortized Discount
Class of Warrant or Right, Exercise Price of Warrants or Rights
Cash paid during the period for:
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Warrants issued for research and development
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
ForfeitureRates
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGranted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Deferred Tax Assets, Valuation Allowance